Artículo
Histamine reduces boron neutron capture therapy-induced mucositis in an oral precancer model
Registro en:
Monti Hughes, A., et al. Histamine reduces boron neutron capture therapy-induced mucositis in an oral precancer model [en línea]. Oral Diseases. 2015, 21 doi:10.1111/odi.12346 Disponible en:
1354-523X
10.1111/odi.12346
25926141
Autor
Monti Hughes, Andrea
Pozzi, Emiliano C. C.
Thorp, S. I.
Curotto, P.
Medina, Vanina Araceli
Martinel Lamas, Diego José
Rivera, Elena S.
Garabalino, M. A.
Farías, R. O.
González, S. J.
Heber, Elisa M.
Itoiz, María E.
Aromando, Romina F.
Nigg, David W.
Trivillin, Verónica A.
Schwint, Amanda E.
Institución
Resumen
Abstract: OBJECTIVES: Searching for more effective and selective therapies for head and neck cancer, we demonstrated the therapeutic effect of boron neutron capture
therapy (BNCT) to treat oral cancer and inhibit longterm tumor development from field-cancerized tissue
in the hamster cheek pouch model. However, BNCTinduced mucositis in field-cancerized tissue was dose
limiting. In a clinical scenario, oral mucositis affects
patients’ treatment and quality of life. Our aim was to
evaluate different radioprotectors, seeking to reduce
the incidence of BNCT-induced severe mucositis in
field-cancerized tissue.
MATERIALS AND METHODS: Cancerized pouches
treated with BNCT mediated by boronophenylalanine
at 5 Gy were treated as follows: control: saline solution;
Hishigh: histamine 5 mg kg 1
; Hislow: histamine
1 mg kg 1
; and JNJ7777120: 10 mg kg 1
.
RESULTS: Hislow reduced the incidence of severe mucositis in field-cancerized tissue to 17% vs CONTROL:
55%; Hishigh: 67%; JNJ7777120: 57%. Hislow was non-toxic
and did not compromise the long-term therapeutic
effect of BNCT or alter gross boron concentration.
Conclusion: Histamine reduces BNCT-induced mucositis in experimental oral precancer without jeopardizing
therapeutic efficacy. The fact that both histamine and
boronophenylalanine are approved for use in humans
bridges the gap between experimental work and
potential clinical application to reduce BNCT-induced
radiotoxicity in patients with head and neck cancer.